RSVpreF

Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases. “At Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies that protect and treat people today while pursuing innovations to expand their impact in the future. Our data at IDWeek 2026 reflects this commitment, with real-world and clinical data across our portfolio as well as important clinical milestones for our next-generation pediatric pneumococcal vaccine candidate and registrational Lyme vaccine candidate. Through these efforts, we are translating scientific advancements into meaningful benefits for communities around the world.” — Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer Key Highlights of Pfizer’s Presence at IDWeek 2026 Advancing Next-Generation Vaccines Across Infectious Diseases Late-breaking presentation of immunogenicity, safety, and tolerability data from a Phase 2 study comparing Pfizer’s 25-valent pneumococcal conjugate vaccine candidate (PF-07872412; 25vPnC) with PREVNAR 20 ® (Pneumococcal 20-valent Conjugate Vaccine) in healthy infants. Topline results from this study were announced in May 2026. These data support the potential of this next-generation vaccine candidate to broaden pneumococcal coverage while informing its ongoing pediatric Phase 3 program. (Presentation Title: Immunogenicity of a 25-valent pneumococcal coverage vaccine compared with PCV20 in healthy infants: Evaluating a candidate to improve pneumococcal coverage in a Phase 2 trial) Safety and immunogenicity data from a Phase 3 study evaluating a single 10-µg dose of Pfizer and BioNTech’s 2025-2026 formula of COMIRNATY ® (COVID-19 Vaccine, mRNA), targeting the LP.8.1 variant of SARS-CoV-2, in children 5-11 years of age at increased risk of severe COVID-19 due to underlying medical conditions. These results further support the safety and robust immunogenicity of the LP.8.1-adapted vaccine in at-risk children. (Presentation Title: Safety and immunogenicity of LP.8.1-adapted BNT162b2 COVID-19 vaccine in children 5–11 years of age) Phase 3 results from the VALOR study of PF-07307405 (LB6V) evaluating the efficacy and safety of LB6V, Pfizer and Valneva’s 6-valent OspA-based Lyme disease vaccine candidate, in healthy participants 5 years of age and older living in Lyme disease-endemic regions of North America and Europe. These results build upon the topline readout announced in March 2026; additionally, the European Medicines Agency (EMA) has started the review of the Marketing Authorization Application (MAA) as announced in August 2026. These findings support the potential to provide clinically meaningful antibody-associated protection of LB6V against Lyme disease. (Presentation Title: Efficacy and safety of the LB6V Lyme disease vaccine candidate: Results from a Phase 3 study in participants ≥5 years of age) Expanding Evidence of Vaccine Impact in Practice Real-world retrospective cohort study evaluating the effectiveness of ABRYSVO ® (Respiratory Syncytial Virus Vaccine) vaccination against laboratory-confirmed RSV infection among Veteran Affairs nursing home residents across three RSV seasons. These results are the first available third-season data for this population and further support RSV vaccination in high-risk older adults while providing important insights into sustained vaccine effectiveness. (Presentation Title: First available vaccine effectiveness of bivalent RSVpreF against laboratory-confirmed RSV infection in nursing home residents through 3 seasons after vaccination — 2025-2026) Multicenter STREETON study evaluating the real-world effectiveness of maternal ABRYSVO vaccination against RSV-associated hospitalization in infants 6 months of age and younger, following the implementation of a national immunization program in Australia. These findings, which are also published in JAMA Pediatrics , support maternal ABRYSVO vaccination and demonstrate protection across infant age groups, disease severity, maternal vaccination characteristics, and RSV subtypes. (Presentation Title: Maternal RSVpreF vaccine effectiveness against respiratory syncytial virus (RSV) in hospitalized infants by age, vaccination characteristics, and RSV subtype: A multicenter test-negative design study in Australia, 2025-2026 (STREETON Study)) Retrospective cohort analysis evaluating the effectiveness of PREVNAR 20 against all-invasive pneumococcal disease (all-IPD) due to any serotype and all-cause pneumonia (ACP) among U.S. adults 65 years of age and older, regardless of prior pneumococcal vaccination history. By demonstrating reductions in all-IPD and ACP, these real-world results underscore the substantial public health impact of PREVNAR 20 when implemented in routine vaccination practice for older adults. (Presentation Title: 20-valent pneumococcal conjugate vaccine: Impact and effectiveness against all-cause outcomes among the general population of US older adults by age group, regardless of prior pneumococcal vaccine history) Modeling study evaluating long-term immunogenicity following a two-dose series of PENBRAYA ® (Meningococcal Groups A, B, C, W, and Y Vaccine), administered to adolescents at extended intervals. These findings indicate that antibodies against meningococcal strain B (MenB) may persist for up to five years, and could offer prolonged protection for higher-risk adolescents alongside a streamlined vaccination schedule that can potentially improve uptake versus current three- or four-dose recommendations. (Presentation Title: Long-term seroprotection following two-dose MenABCWY: Modeling supports benefits of extended dosing intervals) IDWeek Presence Reinforces Pfizer’s Commitment to Addressing the Threat of Infectious Diseases As infectious diseases remain a persistent cause of illness and death worldwide, Pfizer is focused on generating the evidence needed to bring effective vaccines and anti-infective therapies to as many people as possible. Our data at IDWeek reflect that strategy, concentrating innovation in disease areas with the greatest opportunity to impact public health globally, whether through large at-risk populations, the potential for longer-lasting protection, or both. Highlights include emerging data from late-stage investigational programs advancing next-generation vaccines, new analyses supporting established vaccines as standards of care, real-world evidence that deepens understanding of vaccine effectiveness across diverse populations, and several studies surrounding our current and investigational COVID-19 anti-infective therapies. Detailed Presentation Information Information on oral presentations led by Pfizer and its collaborators can be found in the table below. A complete list of presentations is available here . Title/Abstract Number Presenter Date/Time (EDT) Location Early trends for invasive pneumococcal disease in children after the introduction of the 20-valent pneumococcal conjugate vaccine Sheldon Kaplan, MD, Baylor College of Medicine/Texas Children’s Hospital Oct. 22, 11:15 – 11:30 a.m. 103 AB Post-acute sequelae following SARS-CoV-2, influenza, and RSV infection among adults in the prospective community-based Project PROTECTS cohort Avantika Srivastava, MS, City University of New York (CUNY) Institute for Implementation Science in Population Health; Department of Epidemiology and Biostatistics, CUNY School of Public Health and Health Policy Oct. 22, 2:00 – 2:15 p.m. 103 AB Efficacy and safety of the LB6V Lyme disease vaccine candidate: Results from a Phase 3 study in participants ≥5 years of age J.W.R. Hovius, MD, PhD, Amsterdam UMC Multidisciplinary Center for Lyme-borreliosis (AMLC), Amsterdam UMC Oct. 22, 3:15 – 3:27 p.m. 102 AB Quantifying lifetime risk of Lyme disease in the United States: A population-based modeling study Riyadh H. Baksh, MS, Pfizer Oct. 22, 3:51 – 4:03 p.m. 103 AB Long-term seroprotection following two-dose MenABCWY: Modeling supports benefits of extended dosing intervals Jessica Presa, MD, Pfizer Oct. 22, 4:03 – 4:15 p.m. 102 AB Improved virologic control in severely immunocompromised (SIC) adults with COVID-19 receiving extended duration Paxlovid therapy Weihang Bao, PhD, Pfizer Oct. 23, 3:27 – 3:39 p.m. 201 Prevalence of underlying medical conditions associated with increased risk for severe COVID-19 among children under 5 years of age in the United States Laura D. Zambrano, PhD, MPH, Pfizer Oct. 23, 3:51 – 4:03 p.m. 201 Impact of long COVID on medically vulnerable populations: Insights from the expanded ‘Attitudes about COVID and Community Engagement with Patients (ACCEPt)’ survey across 10 countries Frank Spinelli, MD, Pfizer Oct. 23, 4:15 – 4:27 p.m. 201 Maternal RSVpreF vaccine effectiveness against respiratory syncytial virus (RSV) in hospitalized infants by age, vaccination characteristics, and RSV subtype: A multicenter test-negative design study in Australia, 2025-2026 (STREETON Study) Ushma Wadia, MBBS, Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia/Fiona Stanley Hospital/Perth Children’s Hospital Oct. 24, 10:45 – 11:00 a.m. 201 Interim safety of respiratory syncytial virus prefusion F (RSVpreF) vaccine exposure during pregnancy the first two United States vaccination seasons Ashley Michnick, PharmD, PhD, Harvard Pilgrim Health Care Institute, Harvard Medical School Oct. 24, 10:30 – 10:42 a.m. 206 First available vaccine effectiveness of bivalent RSVpreF against laboratory-confirmed RSV infection in nursing home residents through 3 seasons after vaccination — 2025-2026 Brigid Wilson, PhD, VA Northeast Ohio Healthcare Oct. 24, 10:42 – 10:54 a.m. 206 Safety and immunogenicity of LP.8.1-adapted BNT162b2 COVID-19 vaccine in children 5–11 years of age Philip Ponce, MD, Pfizer Oct. 24, 11:06 – 11:18 a.m. 206 Immunogenicity of a 25-valent pneumococcal coverage vaccine compared with PCV20 in healthy infants: Evaluating a candidate to improve pneumococcal coverage in a Phase 2 trial Laurence Flint, MD, MPH, MBA, FAAP, Pfizer Oct. 24, 11:18 – 11:30 a.m. 206 Prescribing Information for Pfizer Medicines Please see full Prescribing Information for ABRYSVO ® (Respiratory Syncytial Virus Vaccine) or visit and . Please see full Prescribing Information for COMIRNATY ® (COVID-19 Vaccine, mRNA) or visit . Please see full Prescribing Information for PAXLOVID ® (nirmatrelvir 150 mg tablets; ritonavir 100 mg tablets) or visit . Please see full Prescribing Information for PENBRAYA ® (Meningococcal Groups A, B, C, W, and Y Vaccine) or visit . Please see full Prescribing Information for PREVNAR 20 ® (Pneumococcal 20-valent Conjugate Vaccine) or visit . About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at . In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer_News , LinkedIn , YouTube and like us on Facebook at . Pfizer Disclosure Notice The information contained in this release is as of October 14, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s infectious disease pipeline, in-line products and product candidates, including their potential benefits, as well as Pfizer’s commitment to addressing the threat of infectious diseases, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s infectious disease products and product candidates; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to changes to vaccine or other healthcare policy in the U.S.; uncertainties regarding the ability to obtain or maintain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations, including uncertainties related to the potential impact of narrowing recommended patient populations; challenges related to public vaccine confidence or awareness; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and . Contacts Pfizer Media Contact: PfizerMediaRelations@Pfizer.com Pfizer Investor Relations: IR@Pfizer.com

10月12日，港股绿竹生物-B（02480.HK）发布自愿性公告，其自主研发的重组呼吸道合胞病毒（RSV）疫苗获国家药监局批准开展临床试验。该产品为液体剂型含铝佐剂疫苗，采用RSV融合前F（Pre-F）蛋白抗原，用于预防RSV引起的下呼吸道疾病（LRTD）。 它传递的信号很直接：国内RSV疫苗赛道，正从个别玩家布局进入密集申报阶段。 每年10万孩子因它去世，却少有人听说：等了60年，RSV疫苗终于上场了01 为什么都在押注RSV：一个长期被低估的呼吸道病原体 呼吸道合胞病毒是常见的呼吸道病原体，易感人群感染后可发展为细支气管炎、肺炎等重症。绿竹生物在公告中明确提示：中国现阶段尚无RSV特异性治疗药物，临床以对症支持治疗为主，对RSV疫苗存在迫切临床需求。 长期以来，RSV被视作婴幼儿病毒，但越来越多的流行病学证据显示，老年人群同样高危。GSK在向中国递交上市申请时引用数据称，RSV每年影响中国超过600万60岁及以上人群。另据公开数据，全球每年约有33.6万例65岁及以上老年人因RSV感染住院，其中约1.4万例住院病例死亡。 值得留意的是，中国老年人群的RSV疾病负担数据仍不完整。2025年底发布的老年人RSV防控专家共识指出，我国相关疾病负担数据仍较匮乏，这也是共识重点呼吁解决的问题。换言之：临床需求真实存在，但国内对这一需求的认识和量化，才刚刚开始。02 进口先行者已经走到上市门口 全球老年RSV疫苗市场，目前由两款产品定义：GSK的Arexvy和辉瑞的Abrysvo。Arexvy于2023年5月获美国FDA批准，是全球首款老年RSV疫苗；辉瑞Abrysvo随后获批，并同时获批孕妇适应症用于保护婴幼儿。 在中国，进口产品已经走到上市门口。2026年2月，国家药监局药品审评中心（CDE）正式受理GSK重组RSV疫苗（CHO细胞，AS01E佐剂系统）60岁及以上成人适应症的上市申请，若获批将成为中国首个获批的老年RSV疫苗。 此前的中国III期临床已披露积极结果：所有主要终点均已达成，疫苗耐受性良好。据GSK披露，单剂Arexvy的保护效力可覆盖三个RSV流行季，累计效力为62.9%。 辉瑞同样在中国推进布局。药物临床试验登记与信息公示平台显示，辉瑞正在中国开展一项60岁及以上成人中评估RSV融合前F蛋白亚单位疫苗安全性、耐受性和免疫原性的III期研究（登记号CTR20251196）。03 国产玩家排队入场：三条技术路线同台 回到国产管线，按公开信息梳理，目前国内RSV疫苗研发大致分三条路线。 第一条是重组蛋白亚单位路线，与GSK同方向。绿竹生物本次获批的液体铝佐剂Pre-F疫苗属此类；走得更快的是艾棣维欣的ADV110，一款含新型佐剂的RSV重组蛋白亚单位疫苗，已完成II期临床并达到所有主要临床终点。 第二条是mRNA路线。沃森生物的呼吸道合胞病毒mRNA疫苗2025年获得临床批件，正开展I期临床准备；康泰生物专门设立mRNA研发团队，聚焦RSV等产品开发。 第三条是黏膜免疫路线。智飞生物全资子公司智飞绿竹的鼻喷重组RSV疫苗（黑猩猩腺病毒载体）于2026年8月获得临床试验申请受理，采用鼻喷黏膜免疫技术路线。 这里有个细节值得注意：智飞生物同时也是GSK在中国的疫苗战略合作伙伴。2023年双方达成独家合作，涵盖Arexvy在华潜在联合开发与商业化。也就是说，同一家公司一边代理进口产品，一边自研差异化路线，两条腿都在走。 04 技术格局与真正的考验 从技术格局看，Pre-F稳定化蛋白是当前已被验证的主流抗原设计，GSK、辉瑞、绿竹、万泰、艾棣维欣均围绕这一方向。差异更多体现在佐剂系统、剂型（液体或冻干）、表达系统（CHO细胞等）以及给药方式（注射或鼻喷）。 对国产玩家而言，真正的考验在临床阶段：老年人群免疫应答偏弱，疫苗需要更强的佐剂和更优的免疫原性设计；国内尚缺人群保护效力数据，III期设计和验证周期不短。绿竹生物也在公告中按港股18A规则提示风险：公司无法保证重组RSV疫苗最终将成功开发及营销。05 接下来该看什么 对行业而言，后续有三个观察点： 一是GSK上市申请的审评进度，首个进口老年RSV疫苗何时获批、如何定价，将直接锚定市场预期； 二是国产管线能否跑出首个III期数据，从临床批件到上市，还有漫长的验证周期； 三是差异化路线（鼻喷黏膜免疫、mRNA）能否证明优势，这决定国产玩家未来是跟随还是换道。 现阶段国内还没有任何一款RSV疫苗可及，所谓打疫苗预防RSV，仍需等待。但产业信号已经清楚：这个被长期低估的老年呼吸道赛道，正在进入国产研发的密集兑现期。参考来源 1. 绿竹生物重组RSV疫苗获国家药监局临床试验批准（2026年10月12日）：液体剂型含铝佐剂、RSV Pre-F蛋白抗原、预防RSV引起的下呼吸道疾病。来源：香港联交所披露易，绿竹生物自愿性公告（公告编号2026101200882_c.pdf）；新浪财经、智通财经、同花顺财经同日报道。 2. GSK重组RSV疫苗（CHO细胞，AS01E佐剂系统）60岁及以上成人适应症上市申请获CDE受理（2026年2月）。来源：葛兰素史克中国官方新闻稿。 3. Arexvy于2023年5月获美国FDA批准，为全球首款老年RSV疫苗。来源：葛兰素史克官方新闻稿、FDA相关公开信息。 4. GSK中国III期试验所有主要终点达成（2026年1月披露）。来源：葛兰素史克中国官方新闻稿。 5. 单剂Arexvy保护效力可覆盖三个RSV流行季，累计效力62.9%。来源：GSK官方新闻稿（2024年9月披露三个流行季数据）。 6. RSV每年影响中国超过600万60岁及以上人群。来源：GSK新闻稿引用。 7. 全球每年约33.6万例65岁及以上老年人因RSV感染住院，其中约1.4万例住院病例死亡。来源：新华网、健康报等引用公开数据。 8. 艾棣维欣ADV110（含新型佐剂RSV重组蛋白亚单位疫苗）完成II期临床并达到所有主要临床终点（2024年8月取得总结报告）。来源：艾棣维欣公告。 9. 智飞绿竹鼻喷重组RSV疫苗（黑猩猩腺病毒载体）临床试验申请获受理（2026年8月10日）。来源：证券时报、智飞绿竹官网新闻中心。 10. 辉瑞在中国开展RSV融合前F蛋白亚单位疫苗III期研究（登记号CTR20251196）。来源：国家药监局药物临床试验登记与信息公示平台。 11. 沃森生物呼吸道合胞病毒mRNA疫苗2025年获《药物临床试验批准通知书》。来源：沃森生物2025年年度报告及投资者关系记录。 识别微信二维码，添加生物制品圈小编，符合条件者即可加入 生物制品微信群！ 请注明：姓名+研究方向！ 版 权 声 明 本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。